References
1. Cronin, K.A., et al., Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer, 2022. 128 (24): p. 4251-4284.
2. Janardan, S.K. and T.P. Miller,Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment. Hematology Am Soc Hematol Educ Program, 2023. 2023 (1): p. 581-586.
3. Ferrari, A., et al.,Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study. Lancet Child Adolesc Health, 2022. 6 (8): p. 545-554.
4. Harrison, D., et al.,Adolescents and Young Adults with Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group Short Running Title: Rhabdomyosarcoma in the AYA Population. Pediatr Blood Cancer, 2024. in press .
5. Trama, A., et al., Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5. Lancet Oncol, 2016.17 (7): p. 896-906.
6. Kirchhoff, A.C., et al.,Access to Care for Adolescent and Young Adults With Cancer in the United States: State of the Literature. J Clin Oncol, 2023: p. JCO2301027.
7. Ferrari, A., et al., Shedding a Light on the Challenges of Adolescents and Young Adults with Rhabdomyosarcoma. Cancers (Basel), 2022. 14 (24).
8. Valtis, Y.K., et al.,Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.Leukemia, 2024.
9. Sultan, I., et al., Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol, 2009. 27 (20): p. 3391-7.
10. Shern, J.F., et al.,Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. J Clin Oncol, 2021.39 (26): p. 2859-2871.